Market Overview:
The global C-MET & HGF inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about cancer treatments, and technological advancements in the field of oncology. The global C-MET & HGF inhibitors market is segmented by type into cabozantinib, crizotinib, and others. By application, the market is segmented into hospital and drug store. Geographically, the global C-MET & HGF inhibitors market is segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
C-MET inhibitors are small molecule drugs that block the activity of the C-MET receptor tyrosine kinase. They are being developed as anticancer agents and have shown efficacy in preclinical models of cancer. HGF inhibitors are small molecules that inhibit the activity of hepatocyte growth factor (HGF), a cytokine that is induced by C-MET and promotes tumor cell proliferation and metastasis.
Cabozantinib:
Cabozantinib is a novel oral inhibitor of Bcr-Abl, developed by Bristol-Myers Squibb. It was approved by the FDA in December 2016 for treatment of patients with metastatic melanoma who have not responded to or are unable to tolerate sunitinib malate and vandolastatine.
It is an oral drug that works through selective inhibition of Bcr-Abl tyrosine kinase activity.
Crizotinib:
Crizotinib is a drug that is developed by the pharmaceutical company Merck. It works by decreasing the activity of platelet-derived growth factor receptor (PDGFR). This reduces blood clotting and helps to reduce the risk of stroke, heart attack, and cancer. The FDA approved this drug in 2013 for treatment of non-small cell lung cancer (NSCLC) which is one type of lung tumor.
Application Insights:
The global market is segmented by application into hospital and drug store. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to the high usage rate of cancer drugs at hospitals as compared to other settings, such as home or clinics. In addition, a large number of anti-cancer drugs are not used due to their cost which forces patients to opt for alternative therapies that do not work as effectively but have lower costs attached with them. However, this trend is expected to change with the introduction of new products under investigational stages that offer better therapeutic benefits at lesser costs thereby providing an impetus for growth over the forecast period.
For instance, cabozantinib (Jakafi) was approved by FDA in December 2017 for use against liver cancer and kidney cancer which were unmet medical needs till then owing to its high cost approximately USD 14,000 per Kg (USD 3 million per year).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. In addition, growing number of C-MET & HGF inhibitors approved by FDA is expected to drive the regional market over the forecast period. For instance, in May 2018 Fycompa was approved by FDA for treatment of Cabozantinib (Zelboraf) has been launched in U.S.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising incidence rates coupled with a large target population base within this region as compared to developed regions such as North America.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for C-MET & HGF inhibitors in the coming years.
- Growing awareness about C-MET & HGF inhibitors: There is a growing awareness among people about the benefits of using C-MET & HGF inhibitors for treating various types of cancers. This is likely to boost the demand for these drugs in the coming years.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D activities to develop new and better drugs that can treat various types of cancers effectively. This is likely to fuel the growth of the C-MET & HGF inhibitors market in future.
Scope Of The Report
Report Attributes
Report Details
Report Title
C-MET & HGF Inhibitors Market Research Report
By Type
Cabozantinib, Crizotinib, Others
By Application
Hospital, Drug Store
By Companies
Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb(BMS), Roche, AVEO Pharmaceuticals, Amgen, AstraZeneca, Mirati Therapeutics, Eli Lilly, Johnson & Johnson, Eisai, Hutchison MediPharma, Kringle Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
208
Number of Tables & Figures
146
Customization Available
Yes, the report can be customized as per your need.
Global C-MET & HGF Inhibitors Market Report Segments:
The global C-MET & HGF Inhibitors market is segmented on the basis of:
Types
Cabozantinib, Crizotinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Exelixis
- Ipsen
- Pfizer
- Novartis
- Takeda
- Merck KGaA
- Merck
- Daiichi Sankyo
- GSK
- Bristol-Myers Squibb(BMS)
- Roche
- AVEO Pharmaceuticals
- Amgen
- AstraZeneca
- Mirati Therapeutics
- Eli Lilly
- Johnson & Johnson
- Eisai
- Hutchison MediPharma
- Kringle Pharmaceuticals
Highlights of The C-MET & HGF Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cabozantinib
- Crizotinib
- Others
- By Application:
- Hospital
- Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the C-MET & HGF Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
C-MET inhibitors are drugs that block the activity of C-Met, a protein that helps cells grow and divide. HGF inhibitors are drugs that block the activity of growth factors such as human growth hormone (HGH).
Some of the major players in the c-met & hgf inhibitors market are Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb(BMS), Roche, AVEO Pharmaceuticals, Amgen, AstraZeneca, Mirati Therapeutics, Eli Lilly, Johnson & Johnson, Eisai, Hutchison MediPharma, Kringle Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 C-MET & HGF Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 C-MET & HGF Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 C-MET & HGF Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the C-MET & HGF Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global C-MET & HGF Inhibitors Market Size & Forecast, 2020-2028
4.5.1 C-MET & HGF Inhibitors Market Size and Y-o-Y Growth
4.5.2 C-MET & HGF Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cabozantinib
5.2.2 Crizotinib
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global C-MET & HGF Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 C-MET & HGF Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cabozantinib
9.6.2 Crizotinib
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cabozantinib
10.6.2 Crizotinib
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cabozantinib
11.6.2 Crizotinib
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cabozantinib
12.6.2 Crizotinib
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cabozantinib
13.6.2 Crizotinib
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 C-MET & HGF Inhibitors Market: Competitive Dashboard
14.2 Global C-MET & HGF Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Exelixis
14.3.2 Ipsen
14.3.3 Pfizer
14.3.4 Novartis
14.3.5 Takeda
14.3.6 Merck KGaA
14.3.7 Merck
14.3.8 Daiichi Sankyo
14.3.9 GSK
14.3.10 Bristol-Myers Squibb(BMS)
14.3.11 Roche
14.3.12 AVEO Pharmaceuticals
14.3.13 Amgen
14.3.14 AstraZeneca
14.3.15 Mirati Therapeutics
14.3.16 Eli Lilly
14.3.17 Johnson & Johnson
14.3.18 Eisai
14.3.19 Hutchison MediPharma
14.3.20 Kringle Pharmaceuticals
